Pharmaceutical News and Articles

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Ingelheim, Germany, January 16, 2025 - Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. (Nasdaq DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with

Bird Flu Found in Georgia Commercial Poultry for First Time

For the first time, bird flu has been detected in a commercial poultry flock in Georgia. The case confirmed in Elbert County by the Georgia Department of Agricu

Seniors Miss Out on Services With Medicare Advantage

Medicare Advantage isn t that great an advantage for seniors compared with traditional Medicare, researchers say. The privatized form of Medicare offers more su

Discontinuing Multifocal Contacts Does Not Diminish Treatment Effect in Myopia

No evidence is seen for loss of treatment effect after discontinuing soft multifocal contact lenses in older teenagers with myopia, according to a study publish

Certain Drug Types Associated With Risk for Dementia

Antimicrobials, vaccines, and anti-inflammatories are associated with a reduced risk for Alzheimer disease and dementia, while antipsychotics and drugs for diab

Increased Intermuscular Fat Linked to Coronary Microvascular Dysfunction

Increased intermuscular fat is associated with coronary microvascular dysfunction (CMD) and adverse cardiovascular outcomes, according to a study published onli

AAP Provides Guidance on Pediatric Fracture Diagnosis, Abuse Assessment

In an American Academy of Pediatrics clinical report published online Jan. 21 in Pediatrics, guidance is presented for the diagnosis of pediatric fractures and

GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and condition

Spravato (esketamine) Approved in the U.S. as the First and Only Monotherapy for Adults with Treatment-Resistant Depression